Skip to search formSkip to main contentSkip to account menu

Doxil

National Institutes of Health

Related topics

Related topics

6 relations
10 ML doxorubicin hydrochloride liposome 2 MG/ML Injection [Doxil]TLC D-99doxorubicin liposome Injection [Doxil]

Broader (3)

Doxorubicindoxorubicin hydrochloride liposomedoxorubicin liposome

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Controlled application and removal of liposomal therapeutics: Effective elimination of pegylated liposomal doxorubicin by double‐filtration plasmapheresis in vitro
Introduction: Nanoscale particle‐based drug delivery systems like long circulating liposomal doxorubicin show unique… 
2008
2008
A Phase I Study of Oral Topotecan and Pegylated Liposomal Doxorubicin (Doxil) in Platinum-Resistant Ovarian and Peritoneal Cancer
Objectives:The feasibility, safety, and preliminary efficacy of a second-line combination therapy for oral topotecan and… 
2005
2005
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma
Multiple myeloma is an incurable disorder of malignant plasma cell. Standard therapy consists of high-dose melphalan followed by… 
2005
2005
Addition of low-dose tumor necrosis factor-&agr; to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats
Improved efficacy of Doxil (STEALTH liposomal doxorubicin) compared to free doxorubicin has been demonstrated in the treatment of… 
Highly Cited
2004
Highly Cited
2004
Tumor necrosis factor‐α augmented tumor response in B16BL6 melanoma‐bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics
The application of tumor necrosis factor‐α (TNF) for the treatment of solid tumors is limited by its severe, life‐threatening… 
2004
2004
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
2004
2004
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors
Introduction: The purpose of this study was to determine the recommended phase II dose (RPTD) of the combination of… 
2002
2002
Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma
Pegylated-liposomal doxorubicin (Doxil™) is a form of liposomal doxorubicin in which the liposomes are coated with methoxypoly… 
2000
2000
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
New therapies are needed for patients with advanced ovarian cancer who relapse after initial treatment with platinum and/or… 
2000
2000
Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma
Twenty-four patients with pleural mesotheliomareceived 50 mg/m2 of Doxil® every four weeks.At follow-up, the disease had… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)